Open Access
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1017 - 1021
Section Les anticorps dans les maladies autres qu’oncologiques
Published online 06 January 2020
  1. Jaddo. Juste après dresseuse d’ours: les histoires brutes et non romancées d’une jeune médecin généraliste. Paris: Fleuve Éditions, 2011: 304 p. [Google Scholar]
  2. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol 2009 ; 10: 816–824. [CrossRef] [PubMed] [Google Scholar]
  3. Richard MA, Corgibet F, Beylot-Barry M, et al. Sex- and age-adjusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the « objectifs peau » study. J Eur Acad Dermatol Venereol 2018 ; 32: 1967–1971. [CrossRef] [PubMed] [Google Scholar]
  4. Sandhu JK, Wu KK, Bui TL, Armstrong AW. Association between atopic dermatitis and suicidality: A systematic review and meta-analysis. JAMA Dermatol 2019 ; 155: 178–187. [CrossRef] [PubMed] [Google Scholar]
  5. Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015 ; 74: 480–489. [CrossRef] [PubMed] [Google Scholar]
  6. Weidinger S, Novak N. Atopic dermatitis. Lancet 2016 ; 387: 1109–1122. [CrossRef] [PubMed] [Google Scholar]
  7. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med 2016 ; 375: 2335–2348. [Google Scholar]
  8. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (liberty ad chronos): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 2017 ; 389: 2287–2303. [CrossRef] [PubMed] [Google Scholar]
  9. Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019 ; 81: 143–151. [CrossRef] [PubMed] [Google Scholar]
  10. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018 ; 32: 850–878. [CrossRef] [PubMed] [Google Scholar]
  11. O’Donnell BF, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997 ; 136: 197–201. [CrossRef] [PubMed] [Google Scholar]
  12. Chang TW, Chen C, Lin CJ, et al. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol 2015 ; 135: 337–342. [CrossRef] [PubMed] [Google Scholar]
  13. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015 ; 135: 67–75. [CrossRef] [PubMed] [Google Scholar]
  14. Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med 2013 ; 368: 924–935. [Google Scholar]
  15. Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013 ; 132: 101–109. [CrossRef] [PubMed] [Google Scholar]
  16. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 2018 ; 73: 1393–1414. [CrossRef] [PubMed] [Google Scholar]
  17. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014 ; 69: 602–616. [CrossRef] [PubMed] [Google Scholar]
  18. Banerji A, Riedl MA, Bernstein JA, et al. Effect of Lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA 2018 ; 320: 2108–2121. [CrossRef] [PubMed] [Google Scholar]
  19. de Bruin-Weller M.. Time to get rid of the investigator’s global assessment as the primary outcome for clinical trials in atopic dermatitis ?. Br J Dermatol 2019 ; 181: 12–13. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.